This study evaluates the effectiveness of the seasonal flu vaccine in adults of different ages and diabetic disease statuses. These studies will help our understanding of how chronic inflammatory diseases impact immunologic function and future research on mitigation strategies.
Our goal is to determine if an individual's level of inflammation determines their response to vaccination. The aging process and certain diseases, like type-2 diabetes, have been characterized as chronic inflammatory conditions. These individuals have higher rates of influenza disease and health care costs; hence, yearly vaccination is recommended. There is a paucity of information comparing vaccination in these high-risk groups and identifying biomarkers that can predict vaccine efficacy. The investigators hypothesize that elderly and diabetic patients have reduced responses to seasonal influenza vaccination that are inversely proportional to their level of chronic inflammation. In this pilot proposal, the investigators will examine adult and elderly diabetic and non-diabetic adults for markers of inflammation and vaccine efficacy before and after influenza vaccination. These studies will help our understanding of how chronic inflammatory diseases impact immunologic function and future research on mitigation strategies.
Study Type
OBSERVATIONAL
Enrollment
164
On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
Tulane Clinical Translational Unit
New Orleans, Louisiana, United States
Change in HAI titer from day 0 to day 30 (+/- 4 days)
Blood samples collected days 0 and 30 will be evaluated and compared for flu antibodies using the standards HAI assay with individual virus strains contained in vaccine.
Time frame: 30 days (+/- 4 days)
Inflammatory Soluble Factor and Cellular Analysis
Inflammatory Analysis will be performed on day 0 samples. Soluble factors in the serum will be analyzed using flow cytometry and bioplex. This analysis will evaluate cellular proliferation, senescence, and recognized inflammatory subsets within myeloid and lymphoid cell subsets.
Time frame: day 0
Inflammatory Soluble Factor and Cellular Analysis additional measurements
Additional Inflammatory Analysis will be performed on day 30 samples. Soluble factors in the serum will be analyzed using flow cytometry and bioplex. This analysis will evaluate cellular proliferation, senescence, and recognized inflammatory subsets within myeloid and lymphoid cell subsets.
Time frame: day 30 (+/- 4 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.